A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE TITRATION, MULTI-CENTER STUDY to EVALUATE the SAFETY and EFFICACY of SUBCUTANEOUS MANP WHEN ADMINISTERED ONCE DAILY for 42 DAYS in PARTICIPANTS with DIFFICULT to CONTROL HYPERTENSION/RESISTANT HYPERTENSION
Latest Information Update: 12 Oct 2024
At a glance
- Drugs M atrial natriuretic peptide (Primary)
- Indications Resistant hypertension
- Focus Adverse reactions; Therapeutic Use
- Acronyms BOLD-HTN
- Sponsors E-Star BioTech
- 12 Oct 2024 New trial record
- 08 Oct 2024 According to an E-Star BioTech media release, the company is currently preparing to enroll their first patient in this trial.
- 08 Oct 2024 According to an E-Star BioTech media release, company announced that it is set to initiate a Phase 2 clinical trial of MANP for the treatment of Resistant Hypertension (BOLD-HTN) supported by a recent round of financing.